The first leading stock of the new crown vaccine is Kangxinuo.
Shanghai, Aug. 13, 2020 (China News Service): Kangxinuo Biological Company Limited (hereinafter referred to as "Kangxinuo") was listed on the Science and Technology Innovation Board (STIB) on the 13th, and became the first "A+H" vaccine stock listed on the STIB. By the end of the day, the company closed at 393.11 yuan per share, up 87.45 percent.
In the "new crown vaccine first shares" "Hong Kong stock vaccine leader" and so on the halo, the market has high expectations for KangXinuo. The issue price of 209.71 yuan per share is the second-highest in the history of China's A-share market, after Beijing Stone Century Science and Technology Co Ltd, which was listed on the Science and Technology Innovation Board (STB) at 271.12 yuan per share.
Extended Information
Concinol develops 16 vaccines in research for 13 disease areas and has obtained 19 authorized invention patents, with a research and development pipeline that covers the prevention of meningitis, Ebola virus disease, DPT, tuberculosis, recombinant neocoronavirus vaccine (adenovirus vector), herpes zoster, and many other vaccines in high clinical demand The company's products have been widely recognized by the public and the public.
The Great Wall Securities said that as a rising star in the vaccine industry, Conocino has high growth potential, and the vaccines to be listed will gradually contribute to the performance of the new coronavirus vaccine research and development progress is in the world's first echelon, and the Ebola virus vaccine has been approved for conditional listing in China, which will usher in a new opportunity for the company's development.
Huajin Securities industry strategy analyst Zhou Xinming also believes that, because there is no specific drug, the vaccine will become an important weapon in the fight against the epidemic, the success of the vaccine is expected to be listed in the market for the relevant vaccine companies to bring greater market value.
CNN - "The first share of the new crown vaccine" Kangxinuo landed on the Science and Technology Innovation Board, closing up more than 87 percent in its debut